Predictors of weight loss in adults with topiramate-treated epilepsy.

Objective: We examined predictors of weight loss with topiramate, an anticonvulsant associated with weight loss in adults.

Research Methods And Procedures: In this uncontrolled, prospective clinical trial, topiramate was added to existing anticonvulsants in adults (40 to 110 kg) with partial-onset seizures. Primary measurements were change from baseline weight after 3 months and 1 year in patients completing 1 year of topiramate treatment (N = 38).